BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37057114)

  • 1. APOBEC mutational signature predicts prognosis and immunotherapy response in nonsmoking patients with lung adenocarcinoma.
    Ma J; Yang X; Zhang J; Antonoff MB; Wu Q; Ji H
    Transl Lung Cancer Res; 2023 Mar; 12(3):580-593. PubMed ID: 37057114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
    Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
    Front Genet; 2022; 13():1017866. PubMed ID: 36699466
    [No Abstract]   [Full Text] [Related]  

  • 3. High Expression of
    Deng H; Huang Y; Wang L; Chen M
    Biomed Res Int; 2020; 2020():2071593. PubMed ID: 33134373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities].
    Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
    Li F; Niu Y; Zhao W; Yan C; Qi Y
    Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Construction and Validation of Prognostic Risk Score Model of Autophagy Related Genes in Lung Adenocarcinoma].
    Zhou J; Wang X; Li Z; Jiang R
    Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):557-566. PubMed ID: 34256900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma.
    Xu Y; Tao T; Li S; Tan S; Liu H; Zhu X
    Front Genet; 2022; 13():975905. PubMed ID: 36313456
    [No Abstract]   [Full Text] [Related]  

  • 9. Apoptosis-Related Signature Predicts Prognosis and Immune Microenvironment Infiltration in Lung Adenocarcinoma.
    Zou X; He R; Zhang Z; Yan Y
    Front Genet; 2022; 13():818403. PubMed ID: 35571020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
    Zeng C; Yu H; Liu X; Liu Q; Jin J
    Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
    Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
    Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
    Cao K; Ling X; Jiang X; Ma J; Zhu J
    Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
    Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
    Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A seven-gene prognostic signature predicts overall survival of patients with lung adenocarcinoma (LUAD).
    Al-Dherasi A; Huang QT; Liao Y; Al-Mosaib S; Hua R; Wang Y; Yu Y; Zhang Y; Zhang X; Huang C; Mousa H; Ge D; Sufiyan S; Bai W; Liu R; Shao Y; Li Y; Zhang J; Shi L; Lv D; Li Z; Liu Q
    Cancer Cell Int; 2021 Jun; 21(1):294. PubMed ID: 34092242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of a Ferroptosis-Related Gene Signature for Overall Survival Prediction in Lung Adenocarcinoma.
    Tian Q; Zhou Y; Zhu L; Gao H; Yang J
    Front Cell Dev Biol; 2021; 9():684259. PubMed ID: 34307361
    [No Abstract]   [Full Text] [Related]  

  • 16. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
    Tang X; Zhou H; Liu Y
    Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel ferroptosis-related genes model for prognosis prediction of lung adenocarcinoma.
    Li F; Ge D; Sun SL
    BMC Pulm Med; 2021 Jul; 21(1):229. PubMed ID: 34256754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
    Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
    Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.